For research use only. Not for therapeutic Use.
Elismetrep（Cat No.:I026793）is an investigational compound under research for its potential therapeutic applications in autoimmune and inflammatory diseases. It works by targeting specific immune system pathways, modulating the activity of immune cells, and potentially reducing inflammation and tissue damage. Elismetrep has shown promise in preclinical studies for treating conditions like rheumatoid arthritis and lupus, where excessive immune responses contribute to disease progression. Ongoing clinical trials aim to assess its safety, efficacy, and optimal dosage. If successful, Elismetrep could offer a novel treatment option for managing chronic inflammatory disorders.
| Catalog Number | I026793 |
| CAS Number | 1400699-64-0 |
| Synonyms | Elismetrep; |
| Molecular Formula | C27H21F3N2O5S |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 4-[(4-cyclopropylisoquinolin-3-yl)-[[4-(trifluoromethoxy)phenyl]methyl]sulfamoyl]benzoic acid |
| InChI | InChI=1S/C27H21F3N2O5S/c28-27(29,30)37-21-11-5-17(6-12-21)16-32(38(35,36)22-13-9-19(10-14-22)26(33)34)25-24(18-7-8-18)23-4-2-1-3-20(23)15-31-25/h1-6,9-15,18H,7-8,16H2,(H,33,34) |
| InChIKey | CWEFDWIKLABKBX-UHFFFAOYSA-N |
| SMILES | C1CC1C2=C(N=CC3=CC=CC=C32)N(CC4=CC=C(C=C4)OC(F)(F)F)S(=O)(=O)C5=CC=C(C=C5)C(=O)O |
